Sanara MedTechSMTI
SMTI
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
380% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 5
28% more capital invested
Capital invested by funds: $24.6M [Q3] → $31.6M (+$7M) [Q4]
16% more funds holding
Funds holding: 44 [Q3] → 51 (+7) [Q4]
1.59% more ownership
Funds ownership: 9.31% [Q3] → 10.9% (+1.59%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$46
51%
upside
Avg. target
$49
60%
upside
High target
$51
68%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Ross Osborn 33% 1-year accuracy 15 / 46 met price target | 51%upside $46 | Overweight Reiterated | 26 Mar 2025 |
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 63 / 167 met price target | 68%upside $51 | Buy Maintained | 26 Mar 2025 |
Financial journalist opinion
Based on 3 articles about SMTI published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Sanara MedTech Inc. (SMTI) Q4 2024 Earnings Call Transcript
Sanara MedTech Inc. (NASDAQ:SMTI ) Q4 2024 Earnings Conference Call March 25, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman and Chief Executive Officer Seth Yon - President, Commercial Sam Muppalla - Tissue Health Plus Tyler Palmer - Chief Corporate Development and Strategy Officer Elizabeth Taylor - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good day, and welcome to the Sanara MedTech Fourth Quarter and Full-Year 2024 Earnings Conference Call. Please not that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly.
Neutral
GlobeNewsWire
1 week ago
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary ● Net revenue increased 49% to $26.3 million, compared to $17.7 million in the fourth quarter of 2023.
Neutral
GlobeNewsWire
3 weeks ago
Sanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its fourth quarter and full year 2024 financial results on Tuesday, March 25, 2025 before the U.S. financial markets open.
Positive
Seeking Alpha
2 months ago
Sanara MedTech: A Promising Growth Story At An Attractive Valuation
Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic opportunities.
Neutral
GlobeNewsWire
2 months ago
Biomimetic Innovations Ltd, an affiliate of PBC Biomed, Announces an Exclusive License and Distribution Agreement and Minority Investment with Sanara MedTech Inc.
SHANNON, Ireland, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Irish medical device company Biomimetic Innovations Limited, an affiliate of PBC Biomed, today announced the execution of an exclusive license and distribution agreement with Sanara MedTech Inc (“Sanara”) (Nasdaq:SMTI). In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Neutral
GlobeNewsWire
2 months ago
Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd
OsStic ® and related technologies represent differentiated solutions that address an estimated 100,000+ procedures in the U.S. annually ( 1) ; arrangement leverages Sanara's existing call points and commercial infrastructure, and complements Sanara's existing surgical portfolio
Neutral
GlobeNewsWire
2 months ago
Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments
Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer
Neutral
GlobeNewsWire
2 months ago
Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024
Fourth Quarter Net Revenue Expected to Increase 45% to 48% Year-Over-Year; Full Year Net Revenue Expected to Increase 32% to 33% Year-Over-Year
Neutral
GlobeNewsWire
4 months ago
Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th
FORT WORTH, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that Ron Nixon, the Company's Chairman and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference, which is being held at The Lotte New York Palace in New York, NY from December 3 – 5, 2024. Mr. Nixon will deliver a presentation to investors on Wednesday, December 4 at approximately 11:50 a.m. Eastern Time.
Positive
Zacks Investment Research
4 months ago
All You Need to Know About Sanara MedTech (SMTI) Rating Upgrade to Buy
Sanara MedTech (SMTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™